Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Conserved oligomeric Golgi complex subunit 1 (**COG1**) is one of eight subunits forming the conserved oligomeric Golgi (COG) complex, a peripheral protein assembly crucial for maintaining normal Golgi morphology, trafficking, and glycosylation function in eukaryotic cells[1][2][4][5][6][7]. COG1 is a member of lobe A of the complex and acts both as a structural scaffold and as a key mediator of retrograde vesicle tethering—enabling proper recycling and localization of Golgi-resident glycosylation enzymes and other proteins[1][2][3][5]. Mutations disrupting COG1 function destabilize the complex and impair Golgi enzyme targeting, resulting in combined defects of N- and O-linked glycosylation and leading to congenital disorders of glycosylation (CDG)[2][3][5][6]. Though critical for Golgi and cellular homeostasis, COG1 is not an enzyme, receptor, or transporter, and has no direct therapeutic ligands; disease is associated solely with loss-of-function and structural instability[1][2][3][4][5][6][7].
Not applicable (no drugs directly targeting COG1)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Conserved oligomeric Golgi complex subunit 1 (COG1).